Implant associated ALCL - version 1.0

• Research type

  Research Study

• Full title

  Identifying mechanisms of implant-associated Anaplastic Large Cell Lymphoma development

• IRAS ID

  214625

• Contact name

  Suzanne D Turner

• Contact email

  sdt36@cam.ac.uk

• Sponsor organisation

  Cambridgeshire & Peterborough NHS Foundation Trust and University of Cambridge

• Duration of Study in the UK

  4 years, 0 months, 1 days

• Research summary

  Summary of Research
  Anaplastic Large Cell Lymphoma (ALCL) is a cancer of the immune system that is most often diagnosed in children and your adults. More recently cases have been reported in the context of women with breast implants. The cancer presents as either a fluid in the capsule surrounding the implant or as a solid mass, often in adjacent lymph nodes. Whilst the former is treated and responds well to implant and capsule removal, the sold masses tend to require chemotherapy and can be fatal if left untreated or diagnosed late. Current research suggests that bacterial infections at the site of the implant drive the progression of this disease although it appears that the material from which the implants are made may also play a role. In order to investigate why and how these tumour develop, we would like to access tumour material/fluid from patients diagnosed with this cancer following surgery and/or fluid removal. This material would be taken as part of routine surgery to diagnose the cancer and/or tumour/implant removal and therefore requires no extra procedures to be performed on the patients. Tumours will be grown in mice and in plastic dishes to allow us to study how it grows and therefore to develop therapies/preventative measures.

  Summary of Results
  Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) is a rare cancer for which it has proven difficult to recruit patients to this study. In part, this is due to patients receiving a diagnosis too late to enrol in our study and also due to the geographical locations of patients. Of the 14 patients that were recruited to the study, the quality of the specimens collected was insufficient for the majority of these. However, we have been able to generate a patient derived xenograft whereby the human cancer cells are propagated through mice for 1 case. The remaining cases have been analysed by DNA sequencing and we are in the process of analysing these data towards publication in the scientific literature

• REC name

  East of Scotland Research Ethics Service REC 1

• REC reference

  17/ES/0047

• Date of REC Opinion

  4 May 2017

• REC opinion

  Further Information Favourable Opinion